- 产品描述
- 产品组分
- 文件资源
- 营销中心
- 注意事项
- FAQ
- 文献追踪
-
Components Microplate, 10X Wash Buffer, Dilution Buffer, PCSK9 Standard, HRP conjugated Detection Antibody, Substrate Reagent, Stop Solution Intended use This Kit is used for the quantitative measurement of Human PCSK9 in serum, plasma, cell culture medium and other biological media. Sample Serum, Plasma, Cell culture medium Measurement range 0.16～10 ng/mL Sensitivity 0.154 ng/mL～ -
产品组分
内容
型号
规格 储存温度
人PCSK9 ELISA检测试剂盒 CNCY8079-01 96次 2-8°C 人PCSK9 ELISA检测试剂盒 CNCY8079-02 192次 2-8°C 操作手册
1 1 常温
-
营销中心
-
注意事项
保存建议 厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。 -
FAQ
-
Noguchi T et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210, 166-172 (2010)(PMID:20006333)
Cariou B et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 211, 700-702 (2010)(PMID:20452593)
Costet P et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non additive fashion in diabetic patients. Atherosclerosis 212, 246-251 (2010)(PMID:20619837)
Noguchi T et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis 217, 165-70 (2011)(PMID:21411093)
Mayne J et al. Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture. Clin Chem. 57,1415 (2011)(PMID:21813713)
Vergès B et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 219, 342-8 (2011)(PMID:21889145)
Lena Persson. Studies on PCSK9 in the regulation of cholesterol metabolism. Published by Karolinska Institutet. Stockholm 2011
Cariou B et al. Clinical aspects of PCSK9. Atherosclerosis. 216, 258-65 (2011)(PMID:21596380)
Persson L et al. Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women. Arterioscler Thromb Vasc Biol. 32, 810-4 (2011)(PMID:22207727)
Kawashiri MA et al. Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 109, 364-9 (2011)(PMID:22112743)
Lindholm MW et al. PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther. 20, 376-81 (2012)(PMID:22108858)
Cameron J et al. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor_independent pathways. Translational Research. 160, 125-30 (2012)(PMID:22683370)
Huijgen R et al. Plasma levels of proprotein convertase subtilisin Kexin type 9 (PCSK9) and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 53, 979-83 (2012)(PMID:22375030)
Cariou B et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab. 10, 4 (2013)(PMID:23298392)
Lee CJ et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 62, 845-50 (2013)(PMID:23380568)
Le Bras M et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab. 98, E732-6 (2013)(PMID:23450051)
Mayne J et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis. 12, 70 (2013)(PMID:23663650)
Peticca P et al. Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. ISRN Endocrinol. 2013, 341632 (2013)(PMID:23862071)
Tremblay AJ et al. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. Am J Clin Nutr. 98, 32-41 (2013)(PMID:23719552)
Conway V et al. Impact of buttermilk consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women. Nutr Metab Cardiovasc Dis. 23, 1255-62 (2013)(PMID:23786821)
Lambert G et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol. 63, 2365-73 (2014)(PMID:24632287)
Werner C et al. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol. 62, 94-102 (2014)(PMID:24685817)
Abujrad H et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 233, 123-9 (2014)(PMID:24529132)
Jia YJ et al. Short- and long-term effects of Xuezhikang (), an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chin J Integr Med. (2014)(PMID:24993334)
Bonde Y et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res. 55, 2408-15 (2014)(PMID:25172631)
Mbikay M et al. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio. 4, 755-62 (2014)(PMID:25349780)
Iggman D et al. Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). J Am Heart Assoc. 3, e001095 (2014)(PMID:25319187)
Xu RX et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis. 13, 188 (2014)(PMID:25496400)
Ghosh M et al. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res. 56, 463-9 (2015)(PMID:25535288)
Xu RX et al. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. J Transl Med. 13, 87 (2015)(PMID:25889684)
Starr AE et al. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. FEBS J. 282, 2682-96 (2015)(PMID:25913303)
Rosqvist F et al. Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study. Am J Clin Nutr. 102, 20-30 (2015)(PMID:26016870)
Butkinaree C et al. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 290, 18609-20 (2015)(PMID:26085104)
van Pelgeest EP et al. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol. 80, 1350-61 (2015)(PMID:26261033)
Wassef H et al. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans. J Clin Lipidol. 9, 664-75 (2015)(PMID:26350813)
Si-Tayeb K et al. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Model Mech. 9, 81-90 (2016)(PMID:26586530)
Rogacev KS et al. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS One 11, e0146920 (2016)(PMID:26799206)
Miasan A et al. Effects of LDL Receptor Modulation on Lymphatic Function. Sci Rep. 6, 27862 (2016)(PMID:27279328)
Vlachopopulos C et al. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis. 252, 50-60 (2016)(PMID:27501130)
Li S et al. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget 8, 12333-12341 (2017)(PMID:27713142)
Navarese EP et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol. 227, 644-649 (2017)(PMID:27810295)
Suzuki Y et al. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates. Int J Pharm. 519, 34-43 (2017)(PMID:28089936)
Li S et al. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Sci Rep. 7, 360 (2017)(PMID:28336922)
Hyrina A et al. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9. EBioMedicine. 23, 68-78 (2017)(PMID:28864162)
Blanchard C et al. Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption. Int J Obes. (2017) In press.(PMID:29135972)
Iacocca MA et al. Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Can J Cardiol. 34, 1316-1324 (2018)(PMID:30269829)
Zhang Z et al. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction. Sci Rep. 9, 3113 (2019) (PMID:30816133)
Merrelaar A et al. Low PCSK-9 levels Are Associated with Favorable Neurologic Function after Resuscitation from out of Hospital Cardiac Arrest. J Clin Med. 9, 2606 (2020)(PMID:32796672)
在线留言
如果您对我们的产品感兴趣，请留下您的信息，我们将尽快与您联系，谢谢！
艾维缔官网
艾德官网
B站IVDSHOW
抖音军哥聊表观
视频号艾维缔
小红书艾维缔
快手表观盒子
表观遗传学
联系我们
